Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

Recruiting N/A Interventional Study
Systemic Scleroderma Diffuse Cutaneous Scleroderma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
65 (estimated)
Sponsor
Boston University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Scleroderma (SSc) is an autoimmune disease characterized by fibrosis (or collagen deposition) of the skin and internal organs. The extent of skin fibrosis is an important predictor of internal organ complications and increased mortality. Currently a very imprecise, subjective method that varies amongst different doctors for the same patient is used to quantify skin fibrosis in patients, by "pinchi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Scleroderma (SSc) participants: * Diagnosed with SSc as defined by the American College of Rheumatology within the past 5 years AND fulfill criteria for diffuse cutaneous SSc according to LeRoy classification * Diagnosed with SSc as defined by the American College of Rheumatol…
Contacts

Benjamin Chamis

617-358-6792

bchamis@bu.edu

CONTACT

Britte Beaudette-Zlatanova, PhD

617-358-6171

britte@bu.edu

CONTACT